ProMIS Neurosciences Announces Second Quarter 2020 Results
(WorldNews Health)

TORONTO, Ontario and CAMBRIDGE, Massachusetts - August 13, 2020 - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (`ProMIS or the Company`), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2020. `Over the course of the second quarter of 2020, the value of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities across multiple neurodegenerative diseases and also in...